Avalo Therapeutics
AVTX
AVTX
65 hedge funds and large institutions have $195M invested in Avalo Therapeutics in 2025 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
81% more funds holding
Funds holding: 36 → 65 (+29)
43.96% more ownership
Funds ownership: 72.44% → 116.39% (+44%)
Holders
65
Holding in Top 10
–
Calls
$1.39M
Puts
$659K
Top Buyers
| 1 | +$9.06M | |
| 2 | +$7.17M | |
| 3 | +$7.03M | |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$6.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.52M |
Top Sellers
| 1 | -$3.63M | |
| 2 | -$2.32M | |
| 3 | -$1.5M | |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$622K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$331K |
